SpyGlass Pharma, Inc. is a late stage biopharmaceutical company focused on transforming the treatment of chronic eye conditions through long acting sustained drug delivery of approved medicines. The company’s lead product candidate is the Bimatoprost Drug Pad IOL System known as the BIM IOL System which combines a drug pad with an intraocular lens to deliver bimatoprost for three years during routine cataract surgery. SpyGlass Pharma is also developing a non IOL based ring shaped sustained release implant called the BIM DRS to provide extended therapy for patients who have already undergone cataract surgery. The underlying technology is the SpyGlass Platform which is designed to work with various small molecule drugs to treat conditions in the front and back of the eye. The company aims to address glaucoma and ocular hypertension by reducing reliance on daily eye drop therapy.

SpyGlass Pharma does not currently generate product sales as its candidates are still in clinical development. The company expects to generate revenue after regulatory approval by selling the BIM IOL System and the BIM DRS to ophthalmic surgery centers hospitals and ambulatory surgery facilities. Revenue will be derived from the product itself and from associated reimbursement for the physician administered drug component. The company anticipates that the IOP lowering portion of the BIM IOL System will be covered under Medicare Part B and billed using a new J code similar to other physician administered drugs. SpyGlass Pharma also plans to leverage existing Category I CPT codes for cataract surgery which simplifies billing and may create additional revenue streams for providers and facilities.

SpyGlass Pharma operates in the competitive ophthalmic drug delivery market where it faces large established companies such as Alcon Allergan AbbVie Bausch & Lomb Glaukos and Johnson & Johnson. These competitors offer topical glaucoma medications laser based interventions MIGS devices and intracameral implants. The company differentiates itself by combining an already approved drug bimatoprost with a widely performed procedure cataract surgery and a standard intraocular lens. This approach allows any cataract surgeon to deliver IOP lowering therapy without needing specialized training for MIGS procedures. SpyGlass Pharma believes its solution can triple the number of surgeons who treat glaucoma at the time of cataract surgery by integrating therapy into the existing workflow. The firm also points to a favorable reimbursement environment under Medicare Part B and a strong intellectual property portfolio as additional competitive advantages.

SpyGlass Pharma’s customers are primarily ophthalmic surgeons who perform cataract surgery including those working in ambulatory surgery centers and hospital based outpatient departments. The company also serves patients with glaucoma or ocular hypertension who are undergoing cataract surgery and seek a long term solution to control intraocular pressure. While the filing does not disclose specific customer names the target market includes the approximately ten thousand cataract surgeons active in the United States and a similar number of surgeons outside the United States. The company expects that adoption will be driven by surgeons looking to simplify their workflow and by facilities seeking additional revenue from physician administered drug reimbursement.